NL-OMON29948尚未招募2 期
A Multicentre, Placebo Controlled, Randomised, Double-blind, Dose Ranging Study of SVT-40776 0.05 mg, 0.1 mg, 0.2 mg, Tolterodine 4 mg and Placebo Daily Doses for 4 Weeks in Patients Suffering from Overactive Bladder Syndrome - SVT-40776
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients suffering from OAB based on three cardinal symptoms (urgency with or without urge incontinence, usually accompanied by frequency or nocturia) for at least 6 months prior to inclusion
- •Patients must document during the 14-day placebo run-in period an average of ><= 10 micturitions/ 24 hours and either a total of ><= 3 incontinence episodes or a total of ><= 3 urgency episodes in the patient diary
排除标准
- •Patients with clinically significant bladder neck obstructions defined as post-void residual urine volumes grater than 100mL.
- •Patients with free uroflow <15 mL/ sec in males or <10 mL/sec in females.
- •Patients with clinically predominant stress incontinence (>=2 episodes per week)
- •Patients suffering from neurologic diseases that could cause neurogenic incontinence.
- •Patients with significant urogenital or gastrointestinal disease.
研究者
相似试验
进行中（未招募）
不适用
A Multicentre, Placebo Controlled, Randomised, Double-blind, Dose Ranging Study of SVT-40776 0.05 mg, 0.1 mg, 0.2 mg, Tolterodine 4 mg and Placebo Daily Doses for 4 Weeks in Patients Suffering from Overactive Bladder SyndromeOveractive bladder (OAB)MedDRA version: 8.1Level: LLTClassification code 10059617EUCTR2006-001378-26-HUaboratorios SALVAT, S.A.315
进行中（未招募）
1 期
A Multicentre, Placebo Controlled, Randomised, Double-blind, Dose Ranging Study of SVT-40776 0.05 mg, 0.1 mg, 0.2 mg, Tolterodine 4 mg and Placebo Daily Doses for 4 Weeks in Patients Suffering from Overactive Bladder SyndromeEUCTR2006-001378-26-NLaboratorios SALVAT, S.A.448
进行中（未招募）
不适用
A Multicentre, Placebo Controlled, Randomised, Double-blind, Dose Ranging Study of SVT-40776 0.05 mg, 0.1 mg, 0.2 mg, Tolterodine 4 mg and Placebo Daily Doses for 4 Weeks in Patients Suffering from Overactive Bladder SyndromeEUCTR2006-001378-26-DEaboratorios SALVAT, S.A.315
进行中（未招募）
不适用
A Multicentre, Placebo Controlled, Randomised, Double-blind, Dose Ranging Study of SVT-40776 0.05 mg, 0.1 mg, 0.2 mg, Tolterodine 4 mg and Placebo Daily Doses for 4 Weeks in Patients Suffering from Overactive Bladder SyndromeOveractive bladder (OAB)MedDRA version: 8.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2006-001378-26-CZaboratorios SALVAT, S.A.315
进行中（未招募）
1 期
ubiprostone for the treatment of paediatric functional constipation study subjects = 6 to < 18 years of agefunctional constipation in paediatric patientsMedDRA version: 18.0Level: PTClassification code 10010774Term: ConstipationSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-003468-30-GBSucampo Pharma Europe Ltd.570